Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847704 | 0.81 | KMT2A (0.38) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL25233643 | 0.79 | ALDH1A1 (0.39) | MAPTKMT2AHTT | |
| SCHEMBL18497250 | 0.78 | SETDB1 (0.47) | MAPT | |
| SCHEMBL18588980 | 0.78 | SLC6A4 (0.42) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL1093855 | 0.78 | KMT2A (0.48) | SLC6A4HTR2AKCNH2SLC6A2MEN1 | |
| SCHEMBL31430877 | 0.76 | KMT2A (0.37) | MEN1MAPTHPGDKMT2APKM | |
| SCHEMBL856508 | 0.76 | KMT2A (0.37) | MEN1MAPTHPGDKMT2APKM | |
| SCHEMBL5046239 | 0.76 | KMT2A (0.35) | MEN1MAPTHPGDKMT2APKM | |
| SCHEMBL1543624 | 0.75 | PDXK (0.46) | MEN1MAPTHPGDKMT2APKM | |
| SCHEMBL15052847 | 0.75 | HTT (0.34) | MEN1MAPTHPGDKMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899334-B1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| EP-1899334-B1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| US-7417054-B2 | Naphthyridine compounds | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-08-26 | — | — | US | disclosed |
| US-7417054-B2 | Naphthyridine compounds | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-08-26 | — | — | US | disclosed |
| US-7417054-B2 | Naphthyridine compounds | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-08-26 | — | — | US | disclosed |
| CN-101243083-A | Naphthyridine compounds | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-13 | — | — | CN | disclosed |
| EP-1899334-A2 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006138714-A2 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287292-A1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287292-A1 | NAPHTHYRIDINE COMPOUNDS | HRH3, HRH4, HRH1 | SLC6A4 10/4885HTR2A 13/4885KCNH2 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.